UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.

If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), ...

The global placental growth factors market is poised for remarkable growth, with projections indicating a surge from USD 34.9 ...

Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $2,688.18 today based on a ...

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...

REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...